Results 141 to 150 of about 292,142 (337)

Molecular and behavioral mechanisms mediating paclitaxel-induced changes in affect-like behavior in mice [PDF]

, 2019
The antineoplastic paclitaxel is associated with negative affective outcomes, such as depression, anxiety, and decreased quality of life during treatment and convalescence. With the Baby Boomer population approaching peak cancer age, it is dire that the
Alkhlaif, Yasmin, Damaj, Imad, Meade, Julia, Obeng, Samuel, Selley, Dana E., Toma, Wisam B   +5 more
core   +1 more source

Ligand-Specific Regulation of the Endogenous Mu-Opioid Receptor by Chronic Treatment with Mu-Opioid Peptide Agonist [PDF]

, 2013
Since the discovery of the endomorphins (EM), the postulated endogenous peptide agonists of the mu-opioid receptors, several analogues have been synthesized to improve their binding and pharmacological profiles.
Birkás, Erika, Bozó, Beáta, Cinar, Resat, Dochnal, Roberta Beatrix, Fábián, Gabriella, Kicsi, Emese Gabriella, Kékesi, Orsolya, Murányi, Marianna, Mácsai, Mónika, Szabó, Gyula, Szűcs, Mária, Tóth, Géza, Zentai, András   +12 more
core   +3 more sources

Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records

PLoS Medicine, 2019
Background Patients with opioid dependency prescribed opioid agonist treatment (OAT) may also be prescribed sedative drugs. This may increase mortality risk but may also increase treatment duration, with overall benefit. We hypothesised that prescription
J. Macleod, C. Steer, K. Tilling, Rosie P. Cornish, J. Marsden, T. Millar, J. Strang, M. Hickman   +7 more
semanticscholar   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Fentanyl assisted treatment: a possible role in the opioid overdose epidemic?

Substance Abuse Treatment, Prevention, and Policy, 2019
Background The current opioid overdose epidemic affecting communities across North America is increasingly driven by illicitly manufactured fentanyl and its related analogues.
Geoff Bardwell, Evan Wood, Rupinder Brar
doaj   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Dopaminergic, glutamatergic but not opioidergic mechanisms mediate induction of FOS-like protein by cocaethylene [PDF]

, 1997
Cocaethylene is a psychoactive metabolite formed\ud during the combined consumption of cocaine and ethanol. As\ud this metabolite has many properties in common with cocaine, it is conceivable that cocaethylene administration may induce the activity of ...
DiPirro, Dr. J.M., Horowitz, Dr. J.M., Kristal, Dr. M.B., Torres, Dr. G.   +3 more
core  

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Nociceptin attenuates the escalation of oxycodone self-administration by normalizing CeA-GABA transmission in highly addicted rats. [PDF]

, 2020
Approximately 25% of patients who are prescribed opioids for chronic pain misuse them, and 5 to 10% develop an opioid use disorder. Although the neurobiological target of opioids is well known, the molecular mechanisms that are responsible for the ...
Carrette, Lieselot LG, de Guglielmo, Giordano, George, Olivier, Kallupi, Marsida, Kononoff, Jenni, Palmer, Abraham A, Schweitzer, Paul, Solberg Woods, Leah C   +7 more
core  

Healthcare utilization and mortality after overdose prevention site closure: A linked cohort analysis using segmented difference‐in‐differences time series

Addiction, EarlyView.
Abstract Background and aims Evidence regarding the impacts of supervised drug consumption services (SDC) remains mixed, and few evaluations have used individual‐level, linkable health data to examine service withdrawal. In September 2024, the Red Deer overdose prevention site (OPS) in Alberta, Canada, was scheduled for closure, with operations ceasing
Nathaniel Day, Kym Kaufmann, Daniel John Alexander Devoe, Vanja Grubac, Alessia DiMarzo, Haisa Osmanli, Vanessa Norton, Shelly Vik, Nickie Mathew, Robert Lawrence Tanguay, Anees Bahji   +10 more
wiley   +1 more source